Gadopiclenol (marketed under the name Elucirem® by Guerbet) receives the JFR* 2024 Innovation Award - Jury's Favorite category

 

prix de l'innovation JFR 2024

Villepinte, 4th October 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, is delighted to announce that Gadopiclenol (marketed as Elucirem® by Guerbet) has been honored with the JFR* 2024 Innovation Award in the Jury's Favorite category.

This contrast agent represents a major advance in the field of magnetic resonance imaging (MRI).

Gadopiclenol is distinguished by its high relaxivity and high stability, providing images of equivalent quality to the macrocyclic gadolinium contrast agents currently available on the market, while using half the dose of gadolinium. Indeed, a dose of 0.05 mmol/kg is sufficient, compared to 0.1 mmol/kg for other macrocyclic gadolinium contrast agents.

Indicated in UE for adults and children 2 years of age and older, Gadopiclenol improves the detection and visualization of conditions associated with disruption of the blood-brain barrier (BBB) and/or abnormal vascularization in:

  • the brain, spine, and other associated tissues of the central nervous system (CNS);
  • the liver, kidney, pancreas, breast, lung, prostate and musculoskeletal system (Elucirem, gadopiclenol (europa.eu).

The Marketing Authorization (MA) for (Gadopiclenol) was granted to Guerbet by the European Commission on December 7, 2023, following approval by the FDA in September 2022.

The award ceremony will take place on October 6 at 12:15 p.m., during the Francophone Days of Radiology at the Palais des Congrès in Paris.

David Hale, CEO, and all Guerbet employees thank the JFR 2024 jury for this prestigious recognition and reaffirm their commitment to pursuing innovation in medical imaging for the benefit of patients and healthcare professionals.

*JFR: journées francophones de la radiologie (Francophone Days of Radiology)

 

About Guerbet

 

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a world leader in medical imaging, offering a complete range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. Pioneers in contrast media for 98 years, with more than 2,920 employees worldwide, we are constantly innovating and devote more than 10% of our revenue to research and development. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €786 million in revenue in 2023. For more information, please visit www.guerbet.com.

 

 

About Gadopiclenol

 

Gadopiclenol, initially invented by Guerbet, with the subsequent contribution of intellectual property held by Bracco, is a new gadolinium-based macrocyclic contrast agent (GBCA) with high relaxivity. The efficacy and safety of Gadopiclenol have been evaluated in MRI of the central nervous system, head and neck, chest, abdomen, pelvis and musculoskeletal system. The Summary of Product Characteristics can be found at  (Elucirem, gadopiclenol (europa.eu).

Details of phase III clinical trials are available in the database of www.ClinicalTrials.gov:

 

About the Guerbet / Bracco Imaging collaboration

 

In December 2021, Bracco Imaging and Guerbet concluded a global collaboration for the production of Gadopiclenol and research and development activities. Gadopiclenol is marketed independently under separate brands. Guerbet and Bracco Imaging each own valuable intellectual property for Gadopiclenol. Furthermore, after an agreed transitional period during which Guerbet will produce Gadopiclenol for both Guerbet and Bracco Imaging, both companies will produce the active ingredient and the finished product Gadopiclenol. This strategic collaboration is expected to accelerate access to Gadopiclenol, innovate and improve care for patients and healthcare professionals.

 

Contacts:

Guerbet    

Christine Allard, Director of Public Affairs and Communication: 33 6 30 11 57 82 / [email protected]